Trial Outcomes & Findings for ATTENUATE (rAdpad proTecTion drapE iN redUcing rAdiaTion Exposure) Trial (NCT NCT06233578)

NCT ID: NCT06233578

Last Updated: 2026-01-28

Results Overview

This is a continuous variable which will be analyzed statistically using the student's t-test.

Recruitment status

COMPLETED

Study phase

NA

Target enrollment

1000 participants

Primary outcome timeframe

From start of each procedure until end of each procedure (up to 1 day)

Results posted on

2026-01-28

Participant Flow

Participant milestones

Participant milestones
Measure
RADPAD
Each cardiac catheterization procedure utilizes the standard guideline directed radiation protocol and a single RADPAD will be placed on the patient. All employee participants will wear a radiation detection device at the level of the left side of the chest facing the radiation source over any the protective apron worn by the participant. RADPAD: The RADPAD protection drape was designed as a protective scatter-radiation absorbing shield with the goal of reducing scatter radiation. It is a sterile, lead free, light weight, and disposable radiation protection shield that is placed directly over the sterile patient drapes. The RADPAD is comprised of antimony and bismuth providing protection during low-energy fluoroscopy and high-energy cine and Digital subtraction angiography (DSA) settings.
No RADPAD
Each cardiac catheterization procedure utilizes the standard guideline directed radiation protocol and no RADPAD will be used. All employee participants will wear a radiation detection device at the level of the left side of the chest facing the radiation source over any the protective apron worn by the participant.
Overall Study
STARTED
500
500
Overall Study
COMPLETED
500
500
Overall Study
NOT COMPLETED
0
0

Reasons for withdrawal

Withdrawal data not reported

Baseline Characteristics

ATTENUATE (rAdpad proTecTion drapE iN redUcing rAdiaTion Exposure) Trial

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure
RADPAD
n=500 Participants
Each cardiac catheterization procedure utilizes the standard guideline directed radiation protocol and a single RADPAD will be placed on the patient. All employee participants will wear a radiation detection device at the level of the left side of the chest facing the radiation source over any the protective apron worn by the participant. RADPAD: The RADPAD protection drape was designed as a protective scatter-radiation absorbing shield with the goal of reducing scatter radiation. It is a sterile, lead free, light weight, and disposable radiation protection shield that is placed directly over the sterile patient drapes. The RADPAD is comprised of antimony and bismuth providing protection during low-energy fluoroscopy and high-energy cine and Digital subtraction angiography (DSA) settings.
No RADPAD
n=500 Participants
Each cardiac catheterization procedure utilizes the standard guideline directed radiation protocol and no RADPAD will be used. All employee participants will wear a radiation detection device at the level of the left side of the chest facing the radiation source over any the protective apron worn by the participant.
Total
n=1000 Participants
Total of all reporting groups
Age, Continuous
68 years
STANDARD_DEVIATION 6.4 • n=41 Participants
70 years
STANDARD_DEVIATION 6.1 • n=1581 Participants
69 years
STANDARD_DEVIATION 6.25 • n=4626 Participants
Sex: Female, Male
Female
205 Participants
n=41 Participants
205 Participants
n=1581 Participants
410 Participants
n=4626 Participants
Sex: Female, Male
Male
295 Participants
n=41 Participants
295 Participants
n=1581 Participants
590 Participants
n=4626 Participants
Race (NIH/OMB)
American Indian or Alaska Native
0 Participants
n=41 Participants
0 Participants
n=1581 Participants
0 Participants
n=4626 Participants
Race (NIH/OMB)
Asian
0 Participants
n=41 Participants
0 Participants
n=1581 Participants
0 Participants
n=4626 Participants
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
0 Participants
n=41 Participants
0 Participants
n=1581 Participants
0 Participants
n=4626 Participants
Race (NIH/OMB)
Black or African American
0 Participants
n=41 Participants
0 Participants
n=1581 Participants
0 Participants
n=4626 Participants
Race (NIH/OMB)
White
0 Participants
n=41 Participants
0 Participants
n=1581 Participants
0 Participants
n=4626 Participants
Race (NIH/OMB)
More than one race
0 Participants
n=41 Participants
0 Participants
n=1581 Participants
0 Participants
n=4626 Participants
Race (NIH/OMB)
Unknown or Not Reported
500 Participants
n=41 Participants
500 Participants
n=1581 Participants
1000 Participants
n=4626 Participants
Region of Enrollment
United States
500 participants
n=41 Participants
500 participants
n=1581 Participants
1000 participants
n=4626 Participants

PRIMARY outcome

Timeframe: From start of each procedure until end of each procedure (up to 1 day)

This is a continuous variable which will be analyzed statistically using the student's t-test.

Outcome measures

Outcome measures
Measure
RADPAD
n=500 Participants
Each cardiac catheterization procedure utilizes the standard guideline directed radiation protocol and a single RADPAD will be placed on the patient. All employee participants will wear a radiation detection device at the level of the left side of the chest facing the radiation source over any the protective apron worn by the participant. RADPAD: The RADPAD protection drape was designed as a protective scatter-radiation absorbing shield with the goal of reducing scatter radiation. It is a sterile, lead free, light weight, and disposable radiation protection shield that is placed directly over the sterile patient drapes. The RADPAD is comprised of antimony and bismuth providing protection during low-energy fluoroscopy and high-energy cine and Digital subtraction angiography (DSA) settings.
No RADPAD
n=500 Participants
Each cardiac catheterization procedure utilizes the standard guideline directed radiation protocol and no RADPAD will be used. All employee participants will wear a radiation detection device at the level of the left side of the chest facing the radiation source over any the protective apron worn by the participant.
Operator Exposure (OE)/Dose Area Product (DAP) (uSv[Micro-Sieverts]/mGy[Milligray]*cm2) of the Proximal Operator
6.41 10,000 x uSv / mGy*cm^2
Standard Deviation 15.56
3.51 10,000 x uSv / mGy*cm^2
Standard Deviation 5.49

PRIMARY outcome

Timeframe: From start of each procedure until end of each procedure (up to 1 day)

This is a continuous variable which will be analyzed statistically using the student's t-test.

Outcome measures

Outcome measures
Measure
RADPAD
n=500 Participants
Each cardiac catheterization procedure utilizes the standard guideline directed radiation protocol and a single RADPAD will be placed on the patient. All employee participants will wear a radiation detection device at the level of the left side of the chest facing the radiation source over any the protective apron worn by the participant. RADPAD: The RADPAD protection drape was designed as a protective scatter-radiation absorbing shield with the goal of reducing scatter radiation. It is a sterile, lead free, light weight, and disposable radiation protection shield that is placed directly over the sterile patient drapes. The RADPAD is comprised of antimony and bismuth providing protection during low-energy fluoroscopy and high-energy cine and Digital subtraction angiography (DSA) settings.
No RADPAD
n=500 Participants
Each cardiac catheterization procedure utilizes the standard guideline directed radiation protocol and no RADPAD will be used. All employee participants will wear a radiation detection device at the level of the left side of the chest facing the radiation source over any the protective apron worn by the participant.
OE/DAP (uSv/mGy*cm2) of the Proximal Operator
6.41 10,000 x uSv / mGy*cm^2
Standard Deviation 15.56
3.51 10,000 x uSv / mGy*cm^2
Standard Deviation 5.49

Adverse Events

RADPAD

Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths

No RADPAD

Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths

Serious adverse events

Adverse event data not reported

Other adverse events

Adverse event data not reported

Additional Information

Giorgio A. Medranda, MD

NYU Langone Health

Phone: (516) 877-2626

Results disclosure agreements

  • Principal investigator is a sponsor employee
  • Publication restrictions are in place